MetaADEDB 2.0 @ LMMD
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
(AUTFSFUMNFDPLH-KYMMNHPFSA-N)
Structure
SMILES
CC(=O)O.OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCCNC(C)C)CC(C)C)Cc1ccc(cc1)NC(=O)N)Cc1ccc(cc1)NC(=O)[C@@H]1CC(=O)NC(=O)N1)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1
Molecular Formula:
C84H107ClN18O18
Molecular Weight:
1692.310
Log P:
7.6567
Hydrogen Bond Acceptor:
36
Hydrogen Bond Donor:
18
TPSA:
550.17
CAS Number(s):
214766-78-6; 934016-19-0
Synonym(s)
1.
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2.
Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2
3.
FE 200486
4.
FE-200486
5.
FE200486
6.
Firmagon
7.
Gonax
8.
degarelix
9.
uglypeptide1
External Link(s)
MeSHC431566
PubChem Compound16144848
16186010
CHEMBLCHEMBL2028987
KEGGdr:D09400
Therapeutic Target DatabaseD01WYT
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1PneumoniaFAERS: 16US FAERS
2Cerebral InfarctionFAERS: 5US FAERS
3Anaphylactic shockFAERS: 4US FAERS
4CellulitisFAERS: 4US FAERS
5FractureFAERS: 4US FAERS
6prostatitisFAERS: 4US FAERS
7Injection site erythemaFAERS: 3US FAERS
8Accidental overdoseFAERS: 2US FAERS
9AstheniaFAERS: 2US FAERS
10Diabetes MellitusFAERS: 2US FAERS
11Injection site cellulitisFAERS: 2US FAERS
12Injection site painFAERS: 2US FAERS
13Myocardial InfarctionFAERS: 2US FAERS
14PancytopeniaFAERS: 2US FAERS
15PyelonephritisFAERS: 2US FAERS
16Respiratory FailureFAERS: 2US FAERS
17Sudden deathFAERS: 2US FAERS
18Aortic anastomosisFAERS: 1US FAERS
19Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
20Blood creatine phosphokinase increasedFAERS: 1US FAERS
21Blood glucose increasedFAERS: 1US FAERS
22Cerebellar infarctionFAERS: 1US FAERS
23Cerebral disorderFAERS: 1US FAERS
24Completed SuicideFAERS: 1US FAERS
25Disease ProgressionFAERS: 1US FAERS
26DizzinessFAERS: 1US FAERS
27Endocrinopathy diencephalicFAERS: 1US FAERS
28GliomaFAERS: 1US FAERS
29HypopituitarismFAERS: 1US FAERS
30HypotensionFAERS: 1US FAERS
31Incorrect dose administeredFAERS: 1US FAERS
32Incorrect route of drug administrationFAERS: 1US FAERS
33IndurationFAERS: 1US FAERS
34Injection site abscessFAERS: 1US FAERS
35Injection site massFAERS: 1US FAERS
36Injection site warmthFAERS: 1US FAERS
37Intentional drug misuseFAERS: 1US FAERS
38Ligament injuryFAERS: 1US FAERS
39MalaiseFAERS: 1US FAERS
40MarasmusFAERS: 1US FAERS
41MonoplegiaFAERS: 1US FAERS
42Musculoskeletal PainFAERS: 1US FAERS
43NauseaFAERS: 1US FAERS
44PainFAERS: 1US FAERS
45Pancreatic carcinomaFAERS: 1US FAERS
46Paraneoplastic neurological syndromeFAERS: 1US FAERS
47PeritonitisFAERS: 1US FAERS
48Prescribed underdoseFAERS: 1US FAERS
49Product use in unapproved indicationFAERS: 1US FAERS
50Product use issueFAERS: 1US FAERS
51RestlessnessFAERS: 1US FAERS
52RhabdomyolysisFAERS: 1US FAERS
53SepsisFAERS: 1US FAERS
54ShockFAERS: 1US FAERS
55Skin UlcerFAERS: 1US FAERS
56Therapy cessationFAERS: 1US FAERS
57TremorFAERS: 1US FAERS
58TuberculosisFAERS: 1US FAERS
59VomitingFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.